Resources from the same session
784O - Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
Presenter: Dirk Schadendorf
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA39 - Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)
Presenter: Reinhard Dummer
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
Presenter: Celeste Lebbe
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
785O - PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)
Presenter: Adi Diab
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA40 and 785O
Presenter: Olivier Michielin
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Slides
Webcast